{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:25:55Z","timestamp":1793042755105,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","award":["MC_UU_00011\/1"],"award-info":[{"award-number":["MC_UU_00011\/1"]}],"id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18OC0052893"],"award-info":[{"award-number":["NNF18OC0052893"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["18-R124-A8511-22089"],"award-info":[{"award-number":["18-R124-A8511-22089"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jacc.2020.09.610","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T15:01:32Z","timestamp":1606748492000},"page":"2725-2735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"title":["VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins"],"prefix":"10.1016","volume":"76","author":[{"given":"Mie","family":"Balling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Varbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.09.610_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib3","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","article-title":"Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease","volume":"96","author":"Nordestgaard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib4","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1161\/01.CIR.99.22.2901","article-title":"Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis","volume":"99","author":"Wittrup","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2020.09.610_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib9","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.09.610_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and\u00a0coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ng.3561","article-title":"Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease","volume":"48","author":"Helgadottir","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2020.09.610_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.09.610_bib17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.09.610_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A\u00a0co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators","volume":"40","author":"Oliver","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacc.2020.09.610_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2020.09.610_bib21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib24","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib25","doi-asserted-by":"crossref","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2020.09.610_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacc.2020.09.610_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish Register of Causes of Death","volume":"39","author":"Helweg-Larsen","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacc.2020.09.610_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacc.2020.09.610_bib32","doi-asserted-by":"crossref","first-page":"11122","DOI":"10.1038\/ncomms11122","article-title":"Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA","volume":"7","author":"Kettunen","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2020.09.610_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/aje\/kwx016","article-title":"Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies","volume":"186","author":"W\u00fcrtz","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib35","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/s41467-019-11311-9","article-title":"A\u00a0metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals","volume":"10","author":"Deelen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2020.09.610_bib36","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A\u00a0test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0021-9150(88)90060-3","article-title":"Hyperglycemia in normotriglyceridemic, hypercholesterolemic insulin-treated diabetic rabbits does not accelerate atherogenesis","volume":"72","author":"Nordestgaard","year":"1988","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2020.09.610_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0021-9150(91)90230-Z","article-title":"Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain","volume":"87","author":"Nordestgaard","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2020.09.610_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","article-title":"A\u00a0third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals","volume":"286","author":"Balling","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2020.09.610_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a010013","article-title":"Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies","volume":"150","author":"Clarke","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1536867X1101100306","article-title":"Comparing coefficients of nested nonlinear probability models","volume":"11","author":"Kohler","year":"2011","journal-title":"Stata Journal"},{"key":"10.1016\/j.jacc.2020.09.610_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in\u00a0vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2020.09.610_bib43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in\u00a0vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.jacc.2020.09.610_bib44","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2020.09.610_bib46","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2020.09.610_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in\u00a0vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2020.09.610_bib48","series-title":"The Metabolic & Molecular Bases of Inherited Disease","first-page":"2835","article-title":"Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism","author":"Mahley","year":"2001"},{"key":"10.1016\/j.jacc.2020.09.610_bib49","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.09.610_bib50","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2020.09.610_bib51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations","volume":"33","author":"Davey Smith","year":"2004","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib52","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.09.610_bib53","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.09.610_bib54","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.09.610_bib55","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2020.09.610_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2020.09.610_bib57","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib58","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib59","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2020.09.610_bib60","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.09.610_bib61","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2020.09.610_bib62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients With Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720374660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720374660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:37:13Z","timestamp":1760017033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720374660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":62,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0735109720374660"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.09.610","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.09.610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}